Exelixis submits cabozantinib NDA to FDA
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. As a part of the NDA filing, which is based on data from a Phase III
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.